Infertility Treatment Drugs

Infertility Treatment Drugs Market Outlook

The global infertility treatment drugs market is anticipated to reach a valuation of approximately USD 3.5 billion by 2035, exhibiting a compound annual growth rate (CAGR) of around 6.2% from 2025 to 2035. This growth can be attributed to several factors, including the rising prevalence of infertility among couples, advancements in reproductive technologies, and increasing awareness about fertility treatments. The emotional and psychological impacts of infertility are prompting more individuals to seek medical assistance, thereby driving the demand for effective infertility treatment drugs. Moreover, the growing trend of delayed pregnancies due to lifestyle choices and socio-economic factors is further propelling the market growth. Additionally, supportive government initiatives and increasing investments in fertility research are expected to create a conducive environment for the expansion of this market.

Growth Factor of the Market

The infertility treatment drugs market is witnessing significant growth due to various factors that are converging to increase demand. One major growth factor is the rising incidence of infertility, with an increasing number of couples struggling to conceive due to health issues, including hormonal imbalances and age-related factors. Furthermore, advancements in fertility treatments and the emergence of new drug formulations are enhancing the effectiveness of infertility medications. Another contributing factor is the increasing acceptance and destigmatization of infertility treatments, leading to more individuals openly seeking help. The digital era has also transformed patient access to information, making it easier for couples to understand their options and leading to a higher inclination towards seeking these treatments. Additionally, the expansion of healthcare infrastructure in developing regions is improving accessibility to infertility treatment drugs, further bolstering the market's growth prospects.

Key Highlights of the Market

• Increasing incidence of infertility driving demand for treatment drugs.
• Advancements in fertility treatment technologies enhancing drug effectiveness.
• Growing acceptance of infertility treatments among the general population.
• Expansion of healthcare services in emerging economies boosting accessibility.
• Research and development efforts leading to innovative drug formulations.

By Product Type

Clomiphene Citrate:

Clomiphene Citrate is widely recognized as one of the first-line medications for treating female infertility, particularly for women with ovulatory dysfunction. This oral medication works by stimulating the pituitary gland to release hormones necessary for ovulation. Its popularity is largely due to its affordability and ease of use, making it a go-to choice for many fertility specialists. The increasing prevalence of conditions such as polycystic ovary syndrome (PCOS), which can lead to infertility, is further fueling the demand for Clomiphene Citrate. Moreover, the drug has a relatively favorable safety profile, contributing to its continued use in fertility treatments. As medical professionals continue to explore its potentials, Clomiphene Citrate remains a fundamental component in the infertility treatment drugs market.

Gonadotropins:

Gonadotropins are a class of fertility medications that play a crucial role in assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF). These injectable drugs stimulate the ovaries to produce multiple eggs, significantly increasing the chances of conception. Gonadotropins are essential for both women with low hormone levels and those undergoing fertility treatments requiring ovarian stimulation. The growing popularity of IVF and other ART procedures has led to a substantial rise in the use of gonadotropins. As more couples pursue assisted reproductive options, the demand for gonadotropins is expected to grow, particularly as advancements in formulations and delivery methods enhance their efficacy and patient convenience.

Metformin:

Metformin, commonly known for its role in managing type 2 diabetes, has also gained attention in the infertility treatment space, especially for women with insulin resistance and PCOS. This medication helps in regulating menstrual cycles and improving ovulatory function, thus enhancing fertility outcomes in women who are overweight or have metabolic disorders. As awareness of the link between metabolic health and fertility continues to rise, the utilization of Metformin in infertility treatments is expected to expand. Additionally, ongoing research into its benefits and potential applications in male infertility may further augment its market presence. The shift towards a holistic approach to fertility, encompassing both reproductive health and metabolic well-being, is positioning Metformin as a relevant treatment option.

Letrozole:

Letrozole is gaining traction as an alternative to Clomiphene Citrate for the treatment of ovulatory disorders, particularly in women with PCOS. This aromatase inhibitor works by lowering estrogen levels, prompting the body to produce more follicle-stimulating hormone (FSH) and thus stimulating ovulation. Recent studies have shown that Letrozole may have a higher success rate in inducing ovulation compared to Clomiphene, making it an increasingly popular choice among fertility specialists. As more clinicians become aware of its benefits, Letrozole's adoption is expected to increase, particularly among women who do not respond well to traditional therapies. The favorable side effect profile of Letrozole further enhances its appeal as a first-line treatment for female infertility.

Bromocriptine:

Bromocriptine is primarily used to treat infertility caused by hyperprolactinemia, a condition characterized by elevated levels of the hormone prolactin. This medication helps normalize prolactin levels, leading to the restoration of normal ovulation and menstrual cycles. As awareness of hormonal imbalances and their impact on fertility grows, the demand for Bromocriptine is expected to rise. Its effectiveness in treating specific fertility issues, coupled with increasing diagnoses of hormonal disorders among women, positions it as a significant player in the infertility treatment drugs market. The ongoing research into its broader applications may further enhance its market share as a specialized treatment for infertility.

By Application

Female Infertility:

The female infertility segment dominates the infertility treatment drugs market, accounting for a significant share of the overall market due to the higher prevalence of infertility issues among women. Factors contributing to female infertility include age, hormonal imbalances, and medical conditions such as endometriosis and PCOS. As women are increasingly delaying childbirth for various reasons, the demand for effective infertility treatments is on the rise. This growing need has led to innovations in drug development specifically aimed at addressing female reproductive health concerns. Moreover, the increasing awareness about women’s health, coupled with advancements in medical technologies, is further driving the segment's growth. Healthcare providers are implementing more personalized treatment plans, contributing to better success rates in female infertility treatments.

Male Infertility:

The male infertility segment is witnessing growth, albeit at a slower pace compared to female infertility. Factors such as low sperm count, poor sperm motility, and hormonal imbalances contribute to male infertility, prompting the need for effective treatment options. Medications like Clomiphene Citrate and Gonadotropins are being increasingly prescribed to males to improve fertility outcomes. As awareness regarding male reproductive health increases, more men are seeking treatment for infertility issues, contributing to the growth of this segment. Additionally, the shift towards comprehensive fertility assessments that evaluate both partners is driving the demand for male infertility treatments, encouraging healthcare providers to develop targeted solutions for male patients.

By Distribution Channel

Hospitals & Clinics:

Hospitals and clinics remain the primary distribution channels for infertility treatment drugs, providing a wide array of services and medications required for fertility treatments. These healthcare facilities are equipped with specialized staff and technologies to diagnose and treat infertility, making them a trusted source for patients. The in-person consultations offered by hospitals and clinics allow for personalized treatment plans and close monitoring of patients’ progress. Furthermore, the availability of comprehensive fertility services, including diagnostic tests and assisted reproductive technologies, enhances the role of these facilities as a one-stop solution for infertility treatments. The growing trend of seeking specialized fertility care is expected to continue driving the demand for infertility drugs through hospitals and clinics.

Online Pharmacies:

Online pharmacies are emerging as a convenient distribution channel for infertility treatment drugs, particularly as the digital landscape continues to evolve. With the increasing reliance on e-commerce, patients are drawn to the convenience of ordering medications from the comfort of their homes, often with the added benefit of discreet delivery. This trend has been further accelerated by the COVID-19 pandemic, which prompted a shift towards online healthcare services. Online pharmacies provide access to a broader range of infertility medications, often at competitive prices. As telehealth services gain popularity, online pharmacies are likely to witness continued growth in the distribution of infertility treatment drugs. However, maintaining quality assurance and legitimate sourcing remains a critical concern for consumers.

Retail Pharmacies:

Retail pharmacies play an essential role as a distribution channel for infertility treatment drugs, particularly for patients seeking immediate access to their medications. These pharmacies are often conveniently located and provide a wide array of fertility medications, making them an accessible option for many patients undergoing treatment. The relationship between pharmacists and patients can lead to valuable counseling opportunities regarding medication adherence and potential side effects. Additionally, as patients increasingly seek personalized care, retail pharmacies are adapting their services to include consultations on infertility medications, which can enhance patient engagement. With a focus on improving customer service, retail pharmacies are positioned to continue serving as a vital resource for infertility treatment drugs.

By Ingredient Type

Progesterone:

Progesterone is a key ingredient in many infertility treatment drugs, playing a crucial role in regulating the menstrual cycle and supporting early pregnancy. Its use is particularly significant in women undergoing assisted reproductive technologies, where maintaining a supportive uterine environment is essential for embryo implantation and growth. Progesterone supplementation is often prescribed to women with luteal phase deficiencies or those undergoing IVF to improve their chances of successful conception. The increasing prevalence of infertility issues, combined with a greater understanding of hormonal treatments, has led to a rising demand for progesterone-based medications. Ongoing research into its broader applications in fertility treatments is likely to further enhance its significance in the market.

Estrogen:

Estrogen is another vital ingredient in infertility treatment drugs, particularly those aimed at women experiencing hormonal imbalances that affect their fertility. This hormone plays a significant role in regulating the menstrual cycle, promoting ovulation, and preparing the uterus for implantation. Estrogen supplements are often used in combination with other fertility medications to enhance the overall effectiveness of treatment protocols. With the increasing awareness of hormonal health and its impact on fertility, the demand for estrogen-based treatments is expected to grow. Furthermore, ongoing research into the mechanisms of estrogen in reproductive health may lead to the development of more targeted therapies, further solidifying its role in infertility treatments.

Testosterone:

Testosterone is primarily associated with male reproductive health and is increasingly being recognized for its role in treating male infertility. Low testosterone levels can impact sperm production and overall fertility in men. Medications containing testosterone are used to address hormonal imbalances, improving sperm quality and fertility outcomes. As awareness of male infertility grows, so does the demand for testosterone-based treatments. This segment is witnessing a shift towards more comprehensive fertility assessments that evaluate both partners, leading to increased focus on male reproductive health. The evolving landscape surrounding male infertility treatments is expected to propel the market for testosterone-containing medications further.

Human Chorionic Gonadotropin:

Human Chorionic Gonadotropin (hCG) is a hormone that plays a vital role in regulating reproductive processes and is often utilized in infertility treatments. hCG is commonly used to trigger ovulation in women undergoing fertility treatments like IVF and intrauterine insemination (IUI). In men, it is used to stimulate testosterone production and support spermatogenesis. The increasing effectiveness of hCG in enhancing fertility outcomes has led to its growing adoption among fertility specialists. As more couples seek assisted reproductive technologies, the demand for hCG is expected to rise significantly, driven by its proven track record in supporting successful pregnancies.

Follicle-Stimulating Hormone:

Follicle-Stimulating Hormone (FSH) is a key player in the regulation of reproductive processes, primarily focusing on the growth and maturation of ovarian follicles in women and stimulating sperm production in men. FSH is crucial in fertility treatments, especially in ovarian stimulation protocols for women undergoing IVF. As more patients opt for assisted reproductive technologies, the demand for FSH is poised to grow. Innovative formulations and delivery methods are also enhancing the effectiveness and convenience of FSH-based treatments. As awareness of fertility issues and available treatment options increases, FSH's role in the market will continue to expand, helping more individuals achieve their reproductive goals.

By Region

The North America region holds a significant share of the infertility treatment drugs market, attributed to advanced healthcare infrastructure, high awareness levels concerning reproductive health, and a growing number of fertility clinics. The market is projected to witness a CAGR of around 5.8% through 2035, driven by the increasing prevalence of infertility, primarily due to lifestyle changes and rising maternal age. The region's emphasis on research and development in reproductive health is leading to innovative treatments and medications, contributing to enhanced patient outcomes. Furthermore, increased insurance coverage for infertility treatments is making healthcare services more accessible to individuals seeking help.

Europe follows closely as a strong market for infertility treatment drugs, driven by a comprehensive healthcare system and rising public awareness about fertility issues. The region is experiencing a growing acceptance of assisted reproductive technologies, leading to increased demand for infertility drugs. The European population's aging demographic and the growing incidence of infertility problems are anticipated to further fuel market growth in this region. As more countries in Europe adopt favorable policies supporting fertility treatments, including financial support and insurance coverage, the overall market for infertility treatment drugs is expected to see consistent growth, aligning with the global trends in reproductive health.

Opportunities

The infertility treatment drugs market is poised for numerous opportunities driven by various factors that can significantly enhance its growth trajectory. One prominent opportunity lies within the realm of research and development, as pharmaceutical companies are increasingly focused on creating innovative treatment options that cater to the diverse needs of patients experiencing infertility. The rising recognition of personalized medicine is prompting the development of tailored treatment plans based on individual genetic and hormonal profiles, leading to improved outcomes for patients. Additionally, the expansion of telehealth services presents a unique opportunity to reach a broader audience, allowing individuals in remote areas to access fertility consultations and treatment options efficiently. As more healthcare providers adopt digital platforms for patient management, the market can expect to see a surge in demand for infertility medications, fostering a more interconnected healthcare ecosystem.

Another significant opportunity lies in the growing awareness regarding male infertility, which has historically received less attention than its female counterpart. As society becomes more knowledgeable about male reproductive health, there is an increased likelihood of men seeking medical assistance for fertility issues. This shift creates an expanding market for male-targeted infertility treatments and drugs tailored to address specific concerns. Furthermore, collaborations between pharmaceutical companies and fertility specialists can drive the development of cutting-edge therapies that maximize patient success rates. With ongoing advancements in reproductive technologies and increasing investment in fertility research, the infertility treatment drugs market is well-positioned to capitalize on these opportunities, leading to enhanced growth and innovation in the coming years.

Threats

Despite the promising outlook for the infertility treatment drugs market, several threats could impede its growth. One of the primary threats is the increasing regulatory scrutiny surrounding pharmaceutical products, particularly fertility medications. Regulatory agencies are continuously implementing stricter guidelines and protocols, which can lead to delays in product approvals and increased compliance costs for manufacturers. These challenges may hinder the market entry of new and innovative treatment options, impacting the overall growth of the sector. Furthermore, the rising prevalence of counterfeit medications poses a significant threat to patient safety and the reputation of legitimate pharmaceutical companies. As patients become increasingly concerned about the authenticity of their medications, the trust in the healthcare system may diminish, resulting in a reluctance to seek infertility treatments altogether.

Another repressive factor is the economic burden associated with infertility treatments, which can be prohibitively expensive for many individuals. While some insurance plans are beginning to provide coverage for fertility treatments, a significant portion of patients remains uninsured or underinsured, creating financial barriers to access. These economic constraints can lead to disparities in treatment outcomes, disproportionately affecting lower-income populations who may not have the means to afford necessary medications. The societal stigma surrounding infertility can also discourage individuals from seeking treatment, perpetuating feelings of isolation and frustration. Together, these threats present challenges that stakeholders must address to ensure continued progress and success within the infertility treatment drugs market.

Competitor Outlook

• Ferring Pharmaceuticals
• Merck KGaA
• Bayer AG
• Novartis AG
• Reproductive Health Technologies
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• HRA Pharma
• IBSA Institute Biochimique SA
• Eisai Co., Ltd.
• Bristol-Myers Squibb Company
• Hatch Fertility
• OvaScience Inc.
• Thermo Fisher Scientific Inc.
• Eli Lilly and Company

The competitive landscape of the infertility treatment drugs market is characterized by the presence of several key players that are continually striving to innovate and capture market share. Companies such as Ferring Pharmaceuticals and Merck KGaA are at the forefront of developing advanced fertility medications and treatments that address diverse patient needs. These organizations invest heavily in research and development, leading to the introduction of new drugs and therapies that enhance patient outcomes and improve success rates in fertility treatments. The competition is intensified by the growing focus on personalized medicine, with many companies exploring genetic and hormonal factors that influence individual responses to infertility treatments.

Additionally, partnerships and collaborations among industry players are becoming increasingly common as companies seek to leverage each other’s strengths and expertise in developing innovative solutions for infertility treatment. For instance, Merck KGaA and Ferring Pharmaceuticals have formed alliances with fertility clinics and research institutions to conduct clinical trials and gather real-world evidence on the effectiveness of their products. This trend towards collaboration not only accelerates the drug development process but also fosters a more integrated approach to addressing the complexities of infertility. The evolving landscape of the infertility treatment drugs market is further marked by the emergence of biotechnology firms focusing on developing novel therapies that challenge traditional treatment paradigms.

Among the major competitors, Bayer AG, Novartis AG, and Pfizer Inc. stand out as influential players due to their extensive portfolios of infertility medications and robust distribution networks. Bayer AG, for instance, is known for its comprehensive offerings that cater to both female and male infertility, combining pharmaceuticals with supportive healthcare services. Similarly, Novartis AG has made significant strides in the research and development of fertility drugs, particularly in the areas of ovarian stimulation and hormonal regulation. Pfizer Inc., with its vast global presence, is leveraging its capabilities to expand access to fertility medications and drive awareness about reproductive health issues. Collectively, these companies are shaping the future of the infertility treatment drugs market, ensuring that innovative solutions are made available to those in need.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 HRA Pharma
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Eisai Co., Ltd.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Hatch Fertility
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 OvaScience Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Eli Lilly and Company
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Ferring Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol-Myers Squibb Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 IBSA Institute Biochimique SA
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Reproductive Health Technologies
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Infertility Treatment Drugs Market, By Application
    • 6.1.1 Female Infertility
    • 6.1.2 Male Infertility
  • 6.2 Infertility Treatment Drugs Market, By Product Type
    • 6.2.1 Clomiphene Citrate
    • 6.2.2 Gonadotropins
    • 6.2.3 Metformin
    • 6.2.4 Letrozole
    • 6.2.5 Bromocriptine
  • 6.3 Infertility Treatment Drugs Market, By Ingredient Type
    • 6.3.1 Progesterone
    • 6.3.2 Estrogen
    • 6.3.3 Testosterone
    • 6.3.4 Human Chorionic Gonadotropin
    • 6.3.5 Follicle-Stimulating Hormone
  • 6.4 Infertility Treatment Drugs Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Online Pharmacies
    • 6.4.3 Retail Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Infertility Treatment Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Infertility Treatment Drugs market is categorized based on

By Product Type

• Clomiphene Citrate
• Gonadotropins
• Metformin
• Letrozole
• Bromocriptine

By Application

• Female Infertility
• Male Infertility

By Distribution Channel

• Hospitals & Clinics
• Online Pharmacies
• Retail Pharmacies

By Ingredient Type

• Progesterone
• Estrogen
• Testosterone
• Human Chorionic Gonadotropin
• Follicle-Stimulating Hormone

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Ferring Pharmaceuticals
• Merck KGaA
• Bayer AG
• Novartis AG
• Reproductive Health Technologies
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• HRA Pharma
• IBSA Institute Biochimique SA
• Eisai Co., Ltd.
• Bristol-Myers Squibb Company
• Hatch Fertility
• OvaScience Inc.
• Thermo Fisher Scientific Inc.
• Eli Lilly and Company